載入...
Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
BACKGROUND: The advent of biologic agents for the treatment of inflammatory bowel disease (IBD) was accompanied in parallel with emerging understanding of persisting underlying inflammation and ensuing bowel damage that can occur even in patients with seeming clinical remission. This lead to the con...
Na minha lista:
| 發表在: | BMC Gastroenterol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4683713/ https://ncbi.nlm.nih.gov/pubmed/26678147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0408-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|